W. Robert Lee

Professor

Duke University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

W. Robert Lee is an Assistant Professor in the Department of Radiation Oncology at Duke University in Durham, North Carolina, USA. His research primarily focuses on health outcomes related to prostate cancer, with a particular emphasis on disparities affecting Black men within and outside the Veterans Health Administration. His recent work aims to reconcile these health outcomes and improve patient care.

Articles (11)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

385 Background: Trials comparing moderately hypofractionated radiotherapy (MHFRT) against conventionally-fractionated radiotherapy (CFRT) for prostate cancer have varied considerably in intent (non-inferiority vs. superiority) and MHFRT dose. Herein, we compare the efficacy and toxicity profiles of isodose MHFRT and dose-escalated MHFRT. Methods: Individual patient data were obtained from 7 phase III trials comparing MHFRT vs. CFRT: three (n=3454) with isodose and four (n=2426) with dose-escalated MHFRT. Meta-analyses were designed to compare progression-free survival (PFS), late grade ≥2 genitourinary (GU) and late grade ≥2 gastrointestinal (GI) physician-scored toxicity, and clinically-significant decrements in patient-reported urinary or bowel quality of life (QOL). Results: After a median follow-up of 5.4 years (interquartile range [IQR], 4.6-7.2) and 7.1 years (IQR 5.7-8.4) following isodose and dose-escalated MHFRT, there were no differences in PFS (hazard ratio [HR] 0.92, 95%CI 0.81-1.05 and HR 0.94, 95%CI 0.82-1.09, respectively). Neither isodose nor dose-escalated MHFRT were associated with increased odds of grade ≥2 GU toxicity (odds ratio [OR] 1.16 95CI% 0.86-1.57 and OR 1.20, 95%CI 0.95-1.51). The odds of grade ≥2 GI toxicity were higher with dose-escalated (OR 1.48, 95%CI 1.14-1.92) but not isodose MHFRT (OR 1.30, 95% 0.59-2.87). Isodose MHFRT did not show different odds of urinary (OR 1.03, 95%CI 0.51-2.09) and bowel (OR 0.76, 95%CI 0.40-1.43) QOL decrements, while dose-escalated MHFRT was associated with greater odds of bowel (OR 1.68, 95%CI 1.07-2.61), but not urinary (OR 1.57, 95%CI 0.87-2.85), QOL decrement. Conclusions: Isodose MHFRT and dose-escalated MHFRT both have similar efficacy compared with CFRT, but dose-escalated MHFRT is associated with higher physician-scored and patient-reported bowel and urinary toxicity. Isodose regimens, e.g. 60 Gy in 20 fractions, should be the standard MHFRT regimen for localized prostate cancer.

Year:

2025

Patients with nonmetastatic, high‐risk prostate cancer are more likely to die of causes unrelated to their cancer. Identifying patients whose competing risks are a greater threat to their mortality has important implications for treatment decisions.

Year:

2022

Year:

2021

Collaborators (12)

John Nikitas

Assistant Professor

University of Pennsylvania

UNITED STATES
View details

Quynh Thu Le

Chair and Professor

Stanford University School of Medicine

UNITED STATES
View details

Donatello Telesca

Professor

University of California Los Angeles Jonathan and Karin Fielding School of Public Health

UNITED STATES
View details

Emma Hall

Institute of Cancer Research

UNITED KINGDOM
View details

Sophia Kamran

Massachusetts General Hospital

UNITED STATES
View details

Wilma Heemsbergen

Researcher

Erasmus University Rotterdam

NETHERLANDS
View details

Paul Corn

Chair

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Susan Halabi

Duke University

UNITED STATES
View details

Juanita Crook

professor

BC Cancer

CANADA
View details

James Bates

Associate Professor

Emory University

UNITED STATES
View details

Luca Incrocci

Full professor

Erasmus University Rotterdam

NETHERLANDS
View details

Deborah W. Bruner

Emory University

UNITED STATES
View details